1. Home
  2. SOHU vs LXRX Comparison

SOHU vs LXRX Comparison

Compare SOHU & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

HOLD

Current Price

$15.64

Market Cap

453.4M

Sector

Technology

ML Signal

HOLD

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.23

Market Cap

425.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOHU
LXRX
Founded
1996
1995
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
453.4M
425.2M
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
SOHU
LXRX
Price
$15.64
$1.23
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$20.00
$3.23
AVG Volume (30 Days)
39.8K
1.6M
Earning Date
11-17-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.11
N/A
Revenue
$576,757,000.00
$70,864,000.00
Revenue This Year
N/A
$56.61
Revenue Next Year
N/A
N/A
P/E Ratio
$3.06
N/A
Revenue Growth
N/A
1255.21
52 Week Low
$7.79
$0.28
52 Week High
$16.45
$1.66

Technical Indicators

Market Signals
Indicator
SOHU
LXRX
Relative Strength Index (RSI) 59.04 43.16
Support Level $14.47 $1.12
Resistance Level $15.72 $1.32
Average True Range (ATR) 0.45 0.09
MACD 0.04 -0.01
Stochastic Oscillator 89.12 31.54

Price Performance

Historical Comparison
SOHU
LXRX

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: